ClinicalTrials.gg
CompletedNCT04931251Updated Oct 7, 2026Results posted

Addressing Cancer-Related Financial Toxicity in North Carolina Oncology Care Settings

An interventional study of Financial Navigation in Neoplasms and Carcinoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Primary conditionCarcinomaRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma
Why
  1. The study's listed conditions name Carcinoma, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Health services research

How we know

Updated Oct 7, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
205
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 403 studies in Carcinoma with a site in United States — 71 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.

Enrollment
68th of 359
205 · median 48
Started
2021
with 16 others
No phase
22 of 403
3 open now
Registered
305th of 403
by date

Among the 403 studies in Carcinoma with a site in United States, this one is the 68th largest by enrollment of the 359 interventional ones that give a count, is one of 17 that started in 2021, is one of 22 with no phase, and was the 305th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

71 of the 403 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The financial burden, or financial toxicity (FT), of cancer is a consequential and growing problem, particularly for rural patients. It is important to improve our understanding of how financial navigation (FN) can reduce the material, psychological, and behavioral burden of costs associated with cancer care in both rural and non-rural community settings. The purpose of this study is to conduct a financial navigation program in 4 rural and 4 non-rural oncology practices in North Carolina and evaluate the effects of financial navigation on patient outcomes, including financial toxicity and health-related quality of life.

Read the detailed description

The objective of this study was to evaluate changes in financial toxicity, as measured by the COmprehensive Score for financial Toxicity (FACIT-COST) from baseline to follow-up after participation in a financial navigation program among rural and non-rural cancer patients in North Carolina with moderate to severe financial toxicity.

After providing informed consent, participants completed the FACIT-COST measure (score range: 0-44, with lower scores indicating greater financial toxicity). Participants with a score of 22 or lower, indicating moderate to severe financial toxicity, were eligible to enroll in the financial navigation intervention. Those with scores of 23 or higher were not eligible.

This implementation study was conducted across eight oncology practices in North Carolina (four rural and four non-rural). Eligible participants completed baseline questionnaires assessing health-related quality of life before meeting with a financial navigator for a comprehensive assessment of financial needs and identification of available financial assistance resources. Participants continued to work with the financial navigator until all appropriate assistance options had been explored and applications, benefits, or referrals were completed.

At the conclusion of the intervention, participants repeated the FACIT-COST measure and baseline questionnaires to assess changes in financial toxicity, health-related quality of life, and the acceptability of the financial navigation program. The intervention typically involved two to six visits with a financial navigator over approximately four months, although participation could extend longer depending on the complexity of the participant's financial needs.

03

Conditions studied

  • Neoplasms
  • Carcinoma

Browse trials for

Keywords

  • Financial Toxicity
  • Cancer
  • Financial Navigation
  • Carcinoma
  • Neoplasms
04

In context

Carcinoma Reclassified

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

This study's enrollment of 205 is above the median of 49 across 571 interventional studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Compared within Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years of age and older
  • Patients with any type of cancer diagnosed within 5 years and/or living with advanced disease
  • Patients who score 22 or lower on the COST measure indicating high FT
  • Patients must be able to read and speak English

Exclusion criteria

Exclusion Criteria:

  • Participants without a cancer diagnosis
  • Patients diagnosed more than 5 years ago without advanced disease
  • Patients or caregivers under the age of 18
  • Patients who do not sign the consent form
  • Patients who do not complete the baseline COST survey
  • Patients who cannot read and speak English
06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • Other
    Financial Navigation

    includes a financial toxicity screening measure (COST), baseline and post-intervention surveys, and approximately 2-6 visits with a financial navigator to identify financial assistance resources

    Behavioral: Financial Navigation

Interventions

  • BehavioralFinancial Navigation

    providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer

07

What researchers measure

Primary outcomes

  1. COST (Comprehensive Score for Financial Toxicity) Measure

    To evaluate changes in financial toxicity from baseline to follow-up, participants completed the 12-item Functional Assessment of Chronic Illness Therapy-Comprehensive Score for Financial Toxicity (FACIT-COST) before and after the financial navigation intervention. FACIT-COST scores range from 0 to 44, with higher scores indicating lower financial toxicity (less financial distress) and lower scores indicating greater financial toxicity (more financial distress). Therefore, an increase in score reflects improvement, whereas a decrease reflects worsening financial toxicity.

    Time frame: 4-6 months

Secondary outcomes

  1. Health-Related Quality of Life (HrQoL) Measures

    To evaluate changes in health-related quality of life (HRQoL) from baseline to follow-up, participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Physical Health, Global Mental Health, Anxiety 6a, Depression 4a, and Psychosocial Illness Impact-Positive instruments. PROMIS T-scores are standardized with a mean of 50 (SD = 10). For Global Physical Health, Global Mental Health, and Psychosocial Illness Impact-Positive, higher scores indicate better health or more positive psychosocial functioning. For Anxiety and Depression, higher scores indicate greater symptom severity; therefore, decreases in these scores reflect improvement, whereas increases reflect worsening symptoms.

    Time frame: 4-6 months

08

Results

Posted Oct 7, 2026

Participant flow

At each of the 8 participating oncology practices, uninsured cancer patients and patients expressing financial concerns on existing distress screening measures or through communication with clinic staff were approached by the financial navigator to participate in this study

Participant flow — Overall Study
MilestoneFinancial Navigation
Started205
Completed179
Not completed26
Withdrew: Lost to follow-up17
Withdrew: Death5
Withdrew: Withdrawal by subject1
Withdrew: Multiple reasons3

Outcome measures

PrimaryCOST (Comprehensive Score for Financial Toxicity) Measure

To evaluate changes in financial toxicity from baseline to follow-up, participants completed the 12-item Functional Assessment of Chronic Illness Therapy-Comprehensive Score for Financial Toxicity (FACIT-COST) before and after the financial navigation intervention. FACIT-COST scores range from 0 to 44, with higher scores indicating lower financial toxicity (less financial distress) and lower scores indicating greater financial toxicity (more financial distress). Therefore, an increase in score reflects improvement, whereas a decrease reflects worsening financial toxicity.

Time frame:
4-6 months
Reported as:
Mean · score on a scale
COST (Comprehensive Score for Financial Toxicity) Measure
score on a scaleBaseline Financial NavigationFollow-up Financial Navigation
COST (Comprehensive Score for Financial Toxicity) Measure6.6 ± 5.114.7 ± 10.2
SecondaryHealth-Related Quality of Life (HrQoL) Measures

To evaluate changes in health-related quality of life (HRQoL) from baseline to follow-up, participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Physical Health, Global Mental Health, Anxiety 6a, Depression 4a, and Psychosocial Illness Impact-Positive instruments. PROMIS T-scores are standardized with a mean of 50 (SD = 10). For Global Physical Health, Global Mental Health, and Psychosocial Illness Impact-Positive, higher scores indicate better health or more positive psychosocial functioning. For Anxiety and Depression, higher scores indicate greater symptom severity; therefore, decreases in these scores reflect improvement, whereas increases reflect worsening symptoms.

Time frame:
4-6 months
Reported as:
Mean · score on a scale
Health-Related Quality of Life (HrQoL) Measures
score on a scaleBaseline Health-Related Quality of Life (HRQoL)Follow-up Health-Related Quality of Life (HRQoL)
Global Mental Health29.76 ± 7.6141.49 ± 7.83
Anxiety62.43 ± 8.5859.10 ± 9.37
Depression57.05 ± 9.6054.98 ± 9.67

Adverse events

Collected over median: 4.5 months; interquartile range (IQR) : 3 - 8 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Financial Navigation5/205 (2.4%)0/205 (0%)0/205 (0%)

Baseline characteristics

Participants began the financial navigation intervention.

Age, Continuous
Age, Continuous(years)Financial Navigation
Mean53.2 (22 to 81)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Financial Navigation
Female132
Male70
Unknown3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Financial Navigation
Hispanic or Latino15
Not Hispanic or Latino190
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Financial Navigation
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American72
White116
More than one race3
Unknown or Not Reported12
Region of Enrollment
Region of Enrollment(Participants)Financial Navigation
United States205
09

Study locations

8 sites
  • NC Basnight Cancer Hospital
    Chapel Hill, North Carolina 27514, United States
  • Novant Health
    Charlotte, North Carolina 28207, United States
  • Vidant Medical Center, Cancer Center
    Greenville, North Carolina 27834, United States
  • Pardee UNC Health Care, Pardee Cancer Center
    Hendersonville, North Carolina 28739, United States
  • UNC Lenoir Cancer Care Services
    Kinston, North Carolina 28501, United States
  • Carteret Health Care Cancer Center
    Morehead City, North Carolina 28557, United States
  • The Outer Banks Hospital
    Nags Head, North Carolina 27959, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
10

References and documents

Publications

  • Wheeler SB, Biddell CB, Manning ML, Gellin MS, Padilla NR, Spees LP, Rogers CD, Rodriguez-O'Donnell J, Samuel-Ryals C, Birken SA, Reeder-Hayes KE, Petermann VM, Deal AM, Rosenstein DL. Lessening the Impact of Financial Toxicity (LIFT): a protocol for a multi-site, single-arm trial examining the effect of financial navigation on financial toxicity in adult patients with cancer in rural and non-rural settings. Trials. 2022 Oct 3;23(1):839. doi: 10.1186/s13063-022-06745-4. PubMed 36192802 ↗
  • Planey AM, Spees LP, Biddell CB, Waters A, Jones EP, Hecht HK, Rosenstein D, Wheeler SB. The intersection of travel burdens and financial hardship in cancer care: a scoping review. JNCI Cancer Spectr. 2024 Sep 2;8(5):pkae093. doi: 10.1093/jncics/pkae093. PubMed 39361410 ↗
  • Wheeler SB, Thom B, Waters AR, Shankaran V. Interventions to Address Cancer-Related Financial Hardship: A Scoping Review and Call to Action. JCO Oncol Pract. 2025 Jan;21(1):29-40. doi: 10.1200/OP.24.00375. Epub 2025 Jan 10. PubMed 39793544 ↗
  • Wheeler SB, Manning ML, Gellin M, Padilla N, Spees LP, Biddell CB, Petermann V, Deal A, Rogers C, Rodriguez-O'Donnell J, Samuel-Ryals C, Reeder-Hayes K, Rosenstein DL. Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity. J Natl Compr Canc Netw. 2024 Oct;22(8):557-562. doi: 10.6004/jnccn.2024.7030. PubMed 39413831 ↗
  • Wheeler SB, Birken SA, Wagi CR, Manning ML, Gellin M, Padilla N, Rogers C, Rodriguez J, Biddell CB, Strom C, Bell RA, Rosenstein DL. Core functions of a financial navigation intervention: An in-depth assessment of the Lessening the Impact of Financial Toxicity (LIFT) intervention to inform adaptation and scale-up in diverse oncology care settings. Front Health Serv. 2022 Nov 9;2:958831. doi: 10.3389/frhs.2022.958831. eCollection 2022. PubMed 36925862 ↗
  • Petermann VM, Biddell CB, Planey AM, Spees LP, Rosenstein DL, Manning M, Gellin M, Padilla N, Samuel-Ryals CA, Birken SA, Reeder-Hayes K, Deal AM, Cabarrus K, Bell RA, Strom C, Young TH, King S, Leutner B, Vestal D, Wheeler SB. Assessing the pre-implementation context for financial navigation in rural and non-rural oncology clinics. Front Health Serv. 2023 Oct 23;3:1148887. doi: 10.3389/frhs.2023.1148887. eCollection 2023. PubMed 37941608 ↗
  • Biddell CB, Spees LP, Petermann V, Rosenstein DL, Manning M, Gellin M, Padilla N, Samuel-Ryals CA, Birken SA, Reeder-Hayes K, Deal AM, Cabarrus K, Bell RA, Strom C, DeAntonio PA, Young TH, King S, Leutner B, Vestal D, Wheeler SB. Financial Assistance Processes and Mechanisms in Rural and Nonrural Oncology Care Settings. JCO Oncol Pract. 2022 Sep;18(9):e1392-e1406. doi: 10.1200/OP.21.00894. Epub 2022 May 12. PubMed 35549521 ↗
  • Waters AR, Thom B, Deal AM, Murray CR, Pignone K, Manning ML, Gellin M, Padilla NR, Spees LP, Planey AM, Reeder-Hayes KE, Rosenstein DL, Wheeler SB. Improvements in Health-Related Quality of Life After Financial Navigation Among Cancer Survivors. Psychooncology. 2026 Sep;35(9):e70605. doi: 10.1002/pon.70605. PubMed 42770487 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified data are available upon reasonable request by contacting the study authors and signing the study Data Use Agreement.

Supporting information: Study protocol

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jul 2025, 44 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 29 interventional studies with no phase under Carcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 18, 2021
StartActual
Nov 11, 2021
Primary completionActual
Jul 31, 2025
CompletionActual
Jul 31, 2025
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Enrollment
258→205
Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedCOST (Comprehensive Score for Financial Toxicity) measureMeasureTime frame: 4-6 months
Oct 7, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42770487 ↗
Oct 7, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionHealth-Related Quality of Life (HrQoL) Measures: how it is measured was reworded
Oct 7, 2026
Title
Addressing Cancer-Related Financial Toxicity in RuralNorth Carolina Oncology Care Settings
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42770487 ↗
    Enrollment 258→205
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedCOST (Comprehensive Score for Financial Toxicity) measureMeasureTime frame: 4-6 months
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionHealth-Related Quality of Life (HrQoL) Measures: how it is measured was reworded
    Title Addressing Cancer-Related Financial Toxicity in RuralNorth Carolina Oncology Care Settings
    + 4 other changes: index terms, verification date, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT04931251
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Nov 11, 2021
Primary completion
Jul 31, 2025
Completion
Jul 31, 2025
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Stephanie Wheeler, PhD
principal investigator · Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion